If you wish to report an adverse event or product complaint, please call 1-800-LILLYRX (1-800-545-5979)
Emgality ® (galcanezumab-gnlm) injection
100 mg/mL, 120 mg/mL
This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.
What is the half-life of Emgality® (galcanezumab-gnlm)?
The elimination half-life of Emgality (galcanezumab) is 27 days.
Pharmacokinetic Characteristics and Half-life of Galcanezumab
Galcanezumab is an immunoglobulin G (subclass 4) monoclonal antibody and is expected to be degraded into small peptides and amino acids via catabolic pathways in the same manner as endogenous immunoglobulin G.1-3
Based on a population pharmacokinetic analysis, the apparent clearance of galcanezumab was approximately 0.008 L/h and the elimination half-life of galcanezumab was 27 days.1-3
Enclosed Prescribing Information
References
The published references below are available by contacting 1-800-LillyRx (1-800-545-5979).
1Emgality [package insert]. Indianapolis, IN: Eli Lilly and Company; 2021.
2Kielbasa W, Helton DL. A new era for migraine: pharmacokinetic and pharmacodynamic insights into monoclonal antibodies with a focus on galcanezumab, an anti-CGRP antibody. Cephalalgia. 2019;39(10):1284-1297. http://dx.doi.org/10.1177/0333102419840780
3Szkutnik-Fiedler D. Pharmacokinetics, pharmacodynamics and drug–drug interactions of new anti-migraine drugs—lasmiditan, gepants, and calcitonin-gene-related peptide (CGRP) receptor monoclonal antibodies. Pharmaceutics. 2020;12(12):1180. https://doi.org/10.3390/pharmaceutics12121180
Date of Last Review: March 30, 2023